TrialThe Lancet. Oncology2018

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

Michael Friedlander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.